04 April 2024
  • Financial press releases
  • Advanced discussions ongoing to secure financing until resumption of early access program (AAC/AAP) expected in Q3 2024
  • Full alignment sought with regulatory agencies prior to launch of a global Phase III trial supporting both US and EU regulatory submissions for registration of LUMEVOQ®
  • Discussions ongoing on strategic options, including M&A and out-licensing

Attachments

  • Original Link
  • Permalink

Disclaimer

Gensight Biologics SA published this content on 04 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 April 2024 17:24:05 UTC.